Patents by Inventor Paul R. Sanberg
Paul R. Sanberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11628190Abstract: A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.Type: GrantFiled: October 17, 2019Date of Patent: April 18, 2023Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.Inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
-
Patent number: 11007230Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by degeneration of motor neurons in the spinal cord and brain. Increasing evidence shows autoimmune mechanisms likely promote disease progression. Human umbilical cord blood (hUCB) derived plasma is rich in cytokines and growth factors that are required for growth and survival of cells during hematopoiesis. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients.Type: GrantFiled: August 29, 2016Date of Patent: May 18, 2021Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.Inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
-
Patent number: 10765706Abstract: Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.Type: GrantFiled: September 6, 2016Date of Patent: September 8, 2020Assignee: University of South FloridaInventors: Cesario Venturina Borlongan, Paul R. Sanberg
-
Publication number: 20200061123Abstract: A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3/7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.Type: ApplicationFiled: October 17, 2019Publication date: February 27, 2020Applicants: University of South Florida, Saneron CCEL Therapeutics, Inc.Inventors: Svitlana Garbuzova-Davis, Jared Carl Ehrhart, Paul R. Sanberg
-
Patent number: 10335434Abstract: The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.Type: GrantFiled: July 21, 2014Date of Patent: July 2, 2019Assignee: University of South FloridaInventors: Paul R. Sanberg, Alison E. Willing
-
Patent number: 10188613Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: GrantFiled: May 3, 2018Date of Patent: January 29, 2019Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Douglas Shytle, Paul R. Sanberg, Mary Newman, Archie A. Silver
-
Patent number: 10130683Abstract: A combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI was tested as a therapeutic for progressive secondary effects of chronic TBI. Rats were treated with saline carrier, or therapeutic in carrier as follows; G-CSF, hUCB, or hUCB and G-CSF, 7-days after TBI. Eight weeks later, behavioral testing was performed and brains harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis. Results revealed that the monotherapies partially suppressed neuroinflammation and reduced hippocampal cell loss. However, combined therapy of hUCB and G-CSF robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions.Type: GrantFiled: August 11, 2015Date of Patent: November 20, 2018Assignee: University of South FloridaInventors: Cesario Venturina Borlongan, Paul R. Sanberg
-
Publication number: 20180325950Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid angiopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: ApplicationFiled: July 16, 2018Publication date: November 15, 2018Applicant: University of South FloridaInventors: Jun Tan, Paul R. Sanberg
-
Publication number: 20180250244Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: May 3, 2018Publication date: September 6, 2018Inventors: DOUGLAS SHYTLE, PAUL R. SANBERG, MARY NEWMAN, ARCHIE A. SILVER
-
Patent number: 10039785Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: GrantFiled: June 28, 2016Date of Patent: August 7, 2018Assignee: University of South FloridaInventors: Jun Tan, Paul R. Sanberg
-
Patent number: 9926354Abstract: The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.Type: GrantFiled: January 9, 2015Date of Patent: March 27, 2018Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Jun Tan, Brian Nelson Giunta, Song Li, Huayan Hou, Paul R. Sanberg
-
Publication number: 20180042968Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: ApplicationFiled: October 23, 2017Publication date: February 15, 2018Applicants: University of South Florida, Saneron CCEL Therapeutics, Inc.Inventors: Paul R. Sanberg, Juan Sanchez-Ramos, Allison Willing, Daniel D. Richard
-
Patent number: 9795637Abstract: The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.Type: GrantFiled: October 9, 2012Date of Patent: October 24, 2017Assignees: University of South Florida, Saneron CCEL Therapeutics, Inc.Inventors: Paul R. Sanberg, Juan Sanchez-Ramos, Alison Willing, Daniel D. Richard
-
Publication number: 20170181983Abstract: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: DOUGLAS SHYTLE, PAUL R. SANBERG, MARY NEWMAN
-
Publication number: 20170143769Abstract: Human umbilical cord blood-derived monocytes that markedly promote A? clearance through heterodimerization of sAPP? with A? and resultant sAPP? production for prevention or treatment of Alzheimer's disease and other neurodegenerative disorders (including stroke and TBI). It was discovered that multiple low-dose infusions of human umbilical cord blood cells (HUCBCs) ameliorate cognitive impairments and reduce A?-associated neuropathology in PSAPP transgenic mice, which markedly promotes amyloid precursor protein (APP) ?-cleavage and resultant sAPP? production for pharmaceutical purposes, in particular for treating or slowing the progression of Alzheimer's disease.Type: ApplicationFiled: November 23, 2016Publication date: May 25, 2017Applicant: University of South FloridaInventors: Jun Tan, Paul R. Sanberg
-
Publication number: 20170065643Abstract: Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.Type: ApplicationFiled: September 6, 2016Publication date: March 9, 2017Applicant: University of South FloridaInventors: Cesario Venturina Borlongan, Paul R. Sanberg
-
Publication number: 20170044225Abstract: The present invention provides fusion peptides, compositions, methods and kits for treating, reducing the risk of, lessening the severity of, preventing, or delaying the onset of amyloid-related disorders, such as Alzheimer's disease and HIV associated neurocognitive impairment.Type: ApplicationFiled: January 9, 2015Publication date: February 16, 2017Applicant: University of South FloridaInventors: Jun TAN, Brian Nelson GIUNTA, Song LI, Huayan HOU, Paul R. SANBERG
-
Publication number: 20160303165Abstract: Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, A? phagocytic activity was increased and soluble and insoluble A? protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of A?1-42 peptide and inhibited immune cell CD40 expression and reduced cerebral amyloid angiopathy.Type: ApplicationFiled: June 28, 2016Publication date: October 20, 2016Applicant: University of South FloridaInventors: Jun Tan, Paul R. Sanberg
-
Patent number: D793944Type: GrantFiled: October 29, 2015Date of Patent: August 8, 2017Assignee: University of South FloridaInventors: Judy Genshaft, Paul R. Sanberg
-
Patent number: D795156Type: GrantFiled: November 10, 2015Date of Patent: August 22, 2017Assignees: University of South Florida, Thomas Jefferson UniversityInventors: Paul R. Sanberg, Stephen Klasko